Highlights from this year’s European Stroke Organisation Conference (ESOC 2021; 1–3 September, virtual), Congress of the European Society of Minimally Invasive Neurological Therapy (ESMINT 2021; 8–10 September, Nice, France and virtual) and LINNC Paris Course (14–16 September, Paris, France and virtual) featured alongside a pioneering piece of research in the neuromodulation field among NeuroNews’ most popular stories during September.
1. Direct mechanical thrombectomy fails to show non-inferiority compared with IV t-PA plus thrombectomy for LVOs
The preliminary results of the SWIFT-DIRECT (Solitaire with the intention for thrombectomy plus IV t-PA versus direct Solitaire stent-retriever thrombectomy in acute anterior circulation stroke) trial have indicated that, in the treatment of large vessel occlusions (LVOs), direct mechanical thrombectomy failed to demonstrate non-inferiority to intravenous tissue-plasminogen activator (IV t-PA) plus thrombectomy—or “bridging thrombolysis”.
Multiple pieces of clinical research supporting the use of flow diverter devices to treat intracranial aneurysms have come to light so far in 2021. The growing body of evidence in favour of using flow diversion technologies for this indication is a “welcome and exciting development”, according to Philip M Meyers of the Neurointervention Clinic at St Luke’s Health System in Boise, USA, who is also past president of the Society of NeuroInterventional Surgery (SNIS) and editor-in-chief of NeuroNews.
This year’s ESMINT Congress saw details of the COATING (Coating to optimise aneurysm treatment in the new flow diverter generation; phenox) study presented by Laurent Pierot, head of the Department of Radiology at the University Hospital of Reims (Reims, France), who is also the study’s principal investigator.
A novel augmented reality (AR) platform (Proximie) has been successfully used to teleproctor a neuroendovascular fellow during complex interventional and diagnostic procedures. That is according to a scientific abstract presented at the 13th Congress of the European Society of Minimally Invasive Neurological Therapy (ESMINT 2021; 8–10 September, Nice, France and virtual).
A new study, published in the peer-reviewed medical journal Aging, marks the first time non-pharmaceutical clinical exploration has proved efficacy in reversing the main activators of Alzheimer’s disease. Using a specific protocol of hyperbaric oxygen therapy (HBOT), cerebral blood flow (CBF) was increased in elderly patients by 16–23%, alleviating vascular dysfunction and amyloid burden.
Sensome announced enrolment of the first patients in the multicentre, first-in-human CLOT OUT study, which will evaluate the safety and performance of the company’s Clotild smart guidewire system in large-vessel acute ischaemic stroke patients. The first patients were enrolled at Gold Coast University Hospital (GCUH) in Gold Coast, Australia.
7. LINNC 2021: ESCAPE-NEXT trial may bring “dream” of combining neuroprotection with EVT closer to reality
At this year’s LINNC Paris Course, audiences heard that the ESCAPE-NEXT trial (sponsored by NoNO Inc.), which has already started enrolling patients and is expected to be completed by August 2022, could represent a major step towards the “dream” therapeutic approach of combining neuroprotection and endovascular therapy (EVT) for acute ischaemic stroke.
8. CRISP study indicates clinical benefit of non-paraesthesia-based approaches in burst SCS lead placement
The CRISP (Comparison of paraesthesia mapping to anatomic midline-based burst programming strategies) study, published in Neuromodulation: Technology at the Neural Interface, has found that equivalent clinical benefits can be achieved in lead placement for burst spinal cord stimulation (SCS) using either conventional paraesthesia mapping, or anatomic landmark-based approaches, in patients with chronic low back pain.
“We are starting to help patients in ways that we did not think were possible,” Thomas Oxley (Mount Sinai Hospital, New York, USA) tells NeuroNews in an exclusive video interview, referring to the potential of brain-computer interface (BCI) technology.
Medtronic announced it has received CE mark approval for its radial artery access portfolio, which includes the Rist radial access selective catheter and the Rist 079 radial access guide catheter—the first catheter specifically designed for the unique demands of accessing the neurovasculature to treat stroke, brain aneurysms and other conditions through the radial artery versus access through the transfemoral artery, according to a company press release.